Eli Lilly announced the positive results of the lebrikizumab Phase 3 registration trial Advance-Asia at the 16th International Atopic Dermatitis Academic Symposium. Research data showed that lebrikizumab maintained good safety and efficacy during the 16-52 week maintenance treatment period in Asian patients with moderate to severe atopic dermatitis, and is expected to bring new options for long-term management of moderate to severe atopic dermatitis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.